This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk01: Good morning and welcome to the Verana Holdings Corp first quarter 2023 earnings conference call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press the star key followed by the number one on your telephone keypad. At this time, I would like to turn the conference over to Juliana Patera, Vice President of Investor Relations. Please go ahead.
spk00: Thank you and good morning, everyone. Welcome to Verano's first quarter 2023 earnings conference call. I am joined today by George Arcos, Chief Executive Officer and Founder, Brett Semerer, Chief Financial Officer, Darren Weiss, Chief Operating Officer, and Aaron Miles, Chief Investment Officer. During this call, we will discuss our business outlook and make forward-looking statements within the meaning of applicable U.S. and Canadian securities laws, which are based on management's current assumptions and expectations. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, and achievements of the business or developments in the company's industry to differ materially from those implied by such forward-looking statements. Actual events or results could differ considerably due to risks and uncertainties mentioned in our filings on EDGAR and CDAR, including our financial statements for the quarter ended March 31, 2023. In addition, throughout today's discussion, we will refer to non-GAAP financial measures that do not have any standardized meaning prescribed by GAAP, such as EBITDA, Adjust EBITDA, and free cash flow. Management believes non-GAAP results are useful to enhance the understanding of the company's ongoing performance, but these are supplemental to and should not be considered in isolation from or as a substitute for GAAP financial measures. These non-GAAP financial measures are defined in our earnings press release and available on our website at investors.morano.com, which also includes the reconciliation of these measures to the most comparable GAAP financial measures. Lastly, all currency is in U.S. dollars unless otherwise noted. I will now turn the call over to George. George, please go ahead.
spk04: Good morning, everyone. I am pleased to report results for another strong quarter, which were in line with our internal expectations. This morning, I will cover the first quarter in more detail and provide an update on our progress towards our free cash flow guidance. I'll then pass it to Brett for a detailed financial review before I conclude with an outlook for the remainder of the year. First quarter 2023 revenue was $227 million, representing 12% year-over-year growth and slight sequential growth. Adjusted EBITDA margin came in at 31%, and notably, we generated positive free cash flow for the quarter. In an industry that uniquely faces a multitude of challenges, we remain very optimistic, especially given this quarter's performance. Top line came in a bit higher than we anticipated as the first quarter is usually softer than the fourth quarter due to seasonality. We've seen steady performance from our portfolio and anticipate seeing upside from new adult use markets, along with the opportunity for deeper penetration and increased market share in existing markets. Near term, we maintain our excitement about the Connecticut market as a leading producer in our adult use program and look forward to adult use sales commencing in Maryland in July. On that note, we were extremely pleased to see Governor Moore of Maryland officially sign adult use legislation into law. We have been preparing for this moment since entering the market in 2017, including optimizing our footprint and expanding our suite of offerings to meet a variety of consumer tastes and preferences. Our efforts have been worthwhile, as sequentially we grew net wholesale revenue by 11% in the first quarter in Maryland. Verano is no stranger to the introduction of an adult use program to an existing medical market. And after being through this many times before, most recently in Connecticut just months ago, we are ready and excited for what we expect to be a robust program launch. We continue to lead the way with a CPG brand performance in Connecticut and are pleased to see steady and robust demand several months after W sales commenced. Retail sales remain strong with sales trending modestly upwards since legalization in January. At the moment, we have one adult use location as our second medical-only location is awaiting zoning approval. Additionally, we anticipate opening our six social equity joint venture dispensaries over the course of the second half of 2023, including our first store within the next 60 days. This expanded footprint will provide the opportunity to increase vertical mix in the state while also supporting social equity efforts in Connecticut. In Florida, we recently took the number two spot in the state in terms of ounces of smokable products sold, while also preserving the pricing integrity of our catalog, a reflection of our higher quality, all-indoor grown flour. We now have 66 move dispensaries across the state, and with a few more planned openings for the year, we anticipate continuing to strengthen our foothold in this medical market in advance of a potential adult use ballot initiative. We are hopeful the current adult use initiative will make the 2024 ballot as we believe that Florida offers the largest opportunity of the state's contemplating adult use legalization. Lastly, in Illinois, as we discussed on the last call, we are optimizing canopy and production in order to appropriately meet demand. This decision is driven in large part by the slower than anticipated pace of new dysmentery openings. Despite these delays, we continue our efforts to streamline operations, increase yields, and introduce new brands and products. For example, in the first quarter, we increased our yields by 23%, along with increasing finished dry grams per employee by 40% versus the prior year. And on the retail side, although sales were roughly flat versus the prior year, we increased dollars per labor hour by nearly 40%, even in a depressed pricing environment. Separately, as none of our retail locations are near the Missouri border, our stores have been largely unaffected by Missouri's recently launched adult use program. As previously discussed, we are tireless in our pursuit of operational excellence. In the first quarter, we increased the sale of Verano products at the retail level by 150% year-over-year and increased dollars per terminal by 63% year-over-year. We are proud of the progress we continue to make and look forward to further improvements that better enable us to serve our markets. Turning to cash flow, we are reiterating our 50 to 75 million free cash flow guidance range, as well as tightening the range of our CapEx guidance to 35 to 50 million. With over 8 million in free cash flow for the quarter, we anticipate free cash flow to accelerate over the course of the year. We feel our operations are stronger than ever with a 17 million in cash flow generated from operations. after slightly decreasing our taxes payable balance while also servicing other cash obligations. As we mentioned in the fourth quarter call, we continue to evaluate production and inventory levels to ensure we are appropriately supplying our markets. As a result, we expect fluctuations in our gross margins throughout the year. Ultimately, we view inventory rightsizing as a positive for the business as it aligns with our goal of appropriately deploying cash. Though this will also impact adjusted EBITDA margins in the short term, this is the right move to build cash reserves and focus on free cash flow generation. I will now pass it to Brett to review our results in further detail before I provide commentary regarding my outlook for the year.
spk09: Thanks, George. I'm very pleased to report strong results for the quarter. First quarter 2023 revenue was $227 million, up 12% compared to the first quarter last year. driven primarily by strength from retail and wholesale adult use sales in New Jersey and Connecticut, slightly offset by retail declines in Pennsylvania. Sequentially, revenue was up 1% despite significantly lower discounting. On a gross revenue basis, excluding intersegment eliminations, 70% was derived from the retail side of the business and 30% from the wholesale side of the business. Gross profit for the quarter was $109 million, or 48% of revenue. On an adjusted basis, generally excluding depreciation, amortization, and stock-based compensation, this was 57%, an improvement of about 1% versus the fourth quarter of 2022, driven by the decreased discounting offset by seven days of inventory reduction. Our sell-through remains high at about 46% for the quarter, excluding Florida, Arkansas, and Michigan, as we do not wholesale in those markets. SG&A expenses were $75 million for the quarter, or 33% of revenue. On an adjusted basis, generally excluding depreciation, amortization, and stock-based compensation, this was 26% of revenue, an improvement of nearly 1% versus the fourth quarter, driven by decreased professional fees and marketing expenses. On an adjusted basis versus the prior year, this is an improvement of 2% due to the right sizing our staffing levels. We expect adjusted SG&A to remain in the 26 to 28% range for the foreseeable future. We had a net loss for the quarter of $9 million and adjusted EBITDA of 71 million or 31% of revenue for the first quarter, down 8 million or four percentage points versus the fourth quarter. However, keep in mind that we had the ERC credit last quarter, which provided a benefit of $11 million or 5% of EBITDA. So we are performing better now than we were in Q4. Turning to the balance sheet and cash flows, we ended the quarter with $95 million in cash and cash equivalents. Cash flow from operations for the quarter was $17 million, even while decreasing our taxes payable balance to $248 million. It's worth pointing out that unlike many in our peer set, Murano has had positive operating cash flow every quarter since we went public. This is our ninth quarter in a row of positive operating cash flow, which includes six quarters of positive free cash flow as well. Regarding taxes payable, we anticipate our tax payable balance to remain around $250 million throughout the year. CapEx spend for the first quarter was $9 million, as some projects from the fourth quarter trickled into the new year. Lastly, we decreased acquisition consideration payable balances by $3 million. Additionally, the majority of the remaining balance was paid in early April, leaving us with de minimis outstanding. I think it's important to note that we have maintained one of the strongest balance sheets in the industry, and we've further committed to strengthening it through the course of the year, which was highlighted in this quarter's performance. Looking ahead, we plan to build our cash balance throughout the year, and we're very comfortable with where we stand today. This was a very strong start for 2023, and I look forward to building off this base throughout the remainder of the year. I'm excited about the opportunities that are in front of us and remain focused on growing the business in the year ahead. And now I'll hand it back to George.
spk04: Thank you, Brett. Although new measures have been introduced at the federal level, as I've said, we never manage the company based on legislative assumptions. We will continue to focus on the business and things in our control while monitoring government actions to make sure we are in a position to take advantage of opportunities that may arise. In the meantime, we continue to operate in a punitive environment that is hindered by government inaction, including the application of 280E to the cannabis industry. which requires us to pay an estimate of greater than $100 million of excess income tax liability for 2022. As a result of the outdated treatment of cannabis at the federal level, we have limited options to manage our banking needs and are forced to take on debt at rates much higher than we think our risk profile warrants. We are extremely proud of what we have been able to accomplish given the draconian restrictions, but there is no telling what we can achieve once we see meaningful legislative change. Despite continued government setbacks, we are managing to not only survive, but thrive. Looking ahead, we are very optimistic given movements in key states, as well as conversations around meaningful reform at the federal level, which continues to have bipartisan support. We have strong footholds in Ohio, Pennsylvania, and Florida, all of which are showing positive momentum towards adult use legalization. This aligns with our strategy of building a strong presence in medical markets so that we are well positioned at the onset of adult use sales. We have successfully done this in Illinois, New Jersey, Connecticut, Nevada, and soon in Maryland. In addition to legalization efforts at the state level, we are seeing progress towards decoupling the application of 280E under federal and state tax laws. Just this week, the New Jersey governor signed a bill unburdening our industry from the onerous impacts of 280E at state level. As we discussed in our last call, New Jersey is among our top three contributors to both retail and wholesale revenue, so we expect an immediate positive impact to our bottom line from this move. Additionally, Connecticut has recently signaled its attempt to decouple 280E and legislation filed on Monday. It's inspiring to see states such as New Jersey and Connecticut take this bold step to support one of the fastest-growing industries in this nation, and I hope to see similar courageous action by leaders across additional states. Regarding the remainder of 2023, I want to echo my sentiments from our last call. We continue to view this year very positively. We are evaluating a number of emitting opportunities, some in new markets, and some deepening our reach in current markets. To reiterate, we remain very selective in evaluating assets to best ensure accretion to our portfolio, especially in light of decreased valuations. We are very excited about Verano's future and the portfolio that we are building. And with that, operator, you can open it up for Q&A.
spk01: At this time, I would like to remind everyone, if you would like to ask a question, please press star 1 on your telephone keypad. Your first question comes from Aaron Gray with Alliance Global Partners.
spk07: Hi. Good morning. Thank you for the question. This is Remy Smith calling for Aaron Gray. So my first question is in regards to Connecticut. It all looks to be a nice state driver for you in the queue. Can you speak to your outlook on the market in 2023? Do you believe there will be additional wholesale opportunities in the market, additional stores opening? And what are you seeing in terms of supply from operators in the market?
spk05: Good morning, Aaron. Thank you for the question. We have a positive outlook on Connecticut. We believe there will be additional wholesale opportunities as retail stores continue to open throughout the state. We also believe that we have some additional vertical integration there as we open our additional six wholesale stores, or our six retail stores with the social equity joint ventures. So we're excited about that entire market. I think the retail stores will start coming online pretty soon here, and it's a good opportunity for us.
spk07: Great, thank you. And then my second question, kind of in regards to your gross margin, your inventory levels. So it's nice to see the sequential gross margin improvement as you work through I know you spoke a little bit in your opening remarks how it might still fluctuate a little bit in 2023. Could you just speak a little bit more now to your comfortability with your inventory levels? And then just in terms of the mix, were those reduction efforts specifically in this quarter more towards pushing the levels of your value price savvy brand, or were those inventories being brought down via other methods?
spk09: Sure. So the overall reduction is across the board. We just want to make sure that we're operating at the leanest level of inventory we can to supply the business. We're targeting about 90 days down from the 117 at the end of the quarter at. We were hoping to get that done in the first half of the year this year. So it would have an impact Q1, Q2. But our inventory reduction in Q1 wasn't quite at the level that we were expecting. So we do expect maybe that trails on into Q3 or so. But overall, yeah, down to 90 days from the 117, and it will continue to impact margins until then. But I think outside of that, you're still going to see our margins in that 59 to 61 sort of percent range. It's been the last five quarters in a row.
spk07: Great. Thank you.
spk01: Your next question comes from the line of Scott Fortune with Roth MKM.
spk02: Yeah, good morning. Thanks for the question here. I just want to provide a little color on kind of future growth opportunities looking into, you know, 24, although that's a ways out. But I just wanted to weigh, you know, your 35 and 50 million in CapEx projects in 23. With these new adult-use states ramping, you've mentioned Connecticut and New Jersey, and we know Maryland coming on in July. But just Wanted to get a sense of the new growth opportunities Rano is evaluating here going forward in light of, you know, prudently allocating your key capital and then follow on with the M&A side of that.
spk05: Yeah, good morning. I mean, we're always looking at, like you just said, M&A opportunities across the country. We have opportunities to go deeper into some of our markets and we're also looking at some new markets as well. We are poised for growth in Pennsylvania, Ohio, and Florida. We think those markets could be transitioned to adult use, so that takes a lot of preparation, so we are focused on those markets. And we have Maryland coming online in July, which you just mentioned, exciting for us, legacy market. We have four retail stores there, a sizable cultivation, and we have decent market share there that will continue to increase as we transition over to adult use. In Connecticut, there's still plenty of opportunity. There's wholesale opportunity there, there's additional retail stores that will be opening So we're excited about what's in our portfolio and very excited about what's to come. Times like this bring opportunities to companies like ours that are strong, and we foresee some very good opportunities here in the next couple of years. There are so many more markets that are transitioning to adult use, new markets coming online with medical. We're applying for new licenses as well. So there's a lot of opportunity in cannabis.
spk03: Hey, Scott, this is Aaron, too. I'll just add one quick point here. You know, you do see a trend in the market where people are pulling back on spend on a necessity, and we're pulling back on spend, to George's point, because, you know, the growth that we see ahead of us in certain markets is slowing. So, we've appropriately built out our footprint, and I think CapEx is following the view we have on the growth potential in certain markets.
spk02: Well, I appreciate that, Keller. And just to follow on, maybe can you characterize the opportunity in Maryland, that state opportunity? Do you see that similar to other states that you've seen in the past that have converged? I know you have a max of four retail there, but it sounds like it's going to be a good wholesale opportunity for you. And not much talk has come about on Ohio, just kind of your sense of the Ohio opportunity and where you got as far as the build-out in Ohio there.
spk05: So Ohio, we're capped on build-out. We just added an additional 3,000 square feet. We'll look to add an additional 3,000 square feet here as time goes on. And depending on how the rules pan out, we have an opportunity to sizably increase that facility. Maryland, we think the opportunity is pretty strong. It is a legacy market. Medical has been around there for quite some time. But the medical market has been declining here the past couple of years in anticipation of adult use. So we think it could be a pretty good jump for us on the wholesale side and on the retail side. I appreciate the color.
spk02: I will jump back in the queue. Thanks.
spk01: Your next question comes from Don Angelo Boalt with Beacon Securities.
spk08: Hey, good morning, and thank you for taking my question. And apologies if you guys have already covered this, but regarding Illinois, what is your latest view on how many new stores might open this year? On the March call, you guys predicted 35 to 45, but noted that the rollout is off to a slower start. Is that 35 to 45 new store openings estimate still intact?
spk05: I think 25 to 30 is probably a better number at this point. We're just seeing a lot of, like as in everywhere else, we're seeing issues with zoning and stores actually getting open. So I think that's probably a pretty good estimate. That being said, if there are groups that have been ready to go with zoning, it could jump higher, which would be obviously a benefit to us and a benefit to the market overall.
spk08: Okay, thank you for the color on that. And then I guess just a follow-up question to that is, beyond access to capital, what are the primary bottlenecks to getting these new stores open?
spk05: Zoning is always the biggest bottleneck, right? It takes time to convince a municipality to add an adult-use store to their city, and then outside of that, you don't want to be stuck in an industrial area, so convincing them to get into a retail area, finding a location, then permitting, et cetera, you're dealing with that have never dealt with cannabis before, so they want to go through security. It's a long, arduous process, and depending on the state that you're in, it can take quite some time.
spk08: Okay. Thank you for the caller. I'll hop back into the queue. Thank you.
spk01: Your next question comes from Andrew Simple with Echelon Capital Markets.
spk10: Hi there. Good morning. Congrats on the solid Q1 results. First off, just want to confirm the quarterly cash flow dynamics. I believe it's Q2 that we typically see a larger pay down of the tax liability or the tax payable. Any idea what we should be penciling into our models for Q2 in terms of paying that down?
spk09: So I think in Q2 we're largely going to be consistent with where we were in Q1. You know, we have a philosophy that we've talked about before that we pay state on time. We pay the federal, you know, within 18 months after filing. And we plan to keep on top of that. But from an outflows perspective, Q1 should look a whole lot like Q2. Q3 and Q4 are a little bit different, mostly because there's no state tax payments in Q4 in general, just the way that they do their payments. the way they do their estimated payments. So you'll see some favorability in Q4 and obviously less in Q3, but that's kind of the cadence. Great, that's helpful.
spk10: And my second question, in the prepared remarks, there's a comment on sales coming in slightly above your internal expectations for Q1. But in response to an earlier question, you also noted that inventory reduction was not progressing quite as fast as anticipated. I'm just trying to reconcile those two comments. And where I'm arriving is, was cultivation yields higher in the first quarter than you were planning for? And if that was the case, would you be thinking about potentially curtailing some grow rooms temporarily in order to reach your targeted inventory levels?
spk09: Sure. So I'll chat a little bit about the financials, and I'll let Darren here talk about what we're doing on the inventory side from an operations perspective. But from a financials perspective, the top line growing and the inventory levels, they're not really tied, right? To a certain degree, you can sell all you want, and it won't really matter from an inventory perspective until you get kind of into the margin. So I think we're comfortable with where we are. In terms of the reductions that we're going through, I think we do intend to
spk07: Hey, this is Jacob on the backup line. I think the main line went out. We're going to get everyone in the backup room real quick.
spk09: I apologize. I don't know where I cut off on that. But just from an inventory perspective, You know, as we make changes to our plans, it does take a little bit of time to play itself out. And the other thing is with rising costs, the amount of dollars in inventory per plant goes up a bit. So those are two kind of factors that play into it.
spk01: This is the operator. One moment. We are having technical difficulties.
Disclaimer